Loading...

Robert O'Donnell

TitlePROF IN RES-HCOMP
InstitutionUniversity of California Davis
DepartmentHematology and Oncology
AddressCancer Ctr So #3016
CA 95817
Phone916-734-3772
vCardDownload vCard

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help.
    List All   |   Timeline
    1. Barisone GA, O'Donnell RT, Ma Y, Abuhay MW, Lundeberg K, Gowda S, Tuscano JM. A purified, fermented, extract of Triticum aestivum has lymphomacidal activity mediated via natural killer cell activation. PLoS One. 2018; 13(1):e0190860. PMID: 29304125.
      View in: PubMed
    2. Abuhay M, Kato J, Tuscano E, Barisone GA, Sidhu RS, O'Donnell RT, Tuscano JM. The HB22.7-vcMMAE antibody-drug conjugate has efficacy against non-Hodgkin lymphoma mouse xenografts with minimal systemic toxicity. Cancer Immunol Immunother. 2016 Oct; 65(10):1169-75. PMID: 27506529.
      View in: PubMed
    3. Kong Y, Barisone GA, Sidhu RS, O'donnell RT, Tuscano JM. Efficacy of Combined Histone Deacetylase and Checkpoint Kinase Inhibition in a Preclinical Model of Human Burkitt Lymphoma. Mol Med. 2015 Aug 24. PMID: 26322845.
      View in: PubMed
    4. Kong Y, Barisone GA, Abuhay M, O'Donnell RT, Buksh Z, Yousefian F, Tuscano JM. Histone deacetylase inhibition enhances the lymphomacidal activity of the anti-CD22 monoclonal antibody HB22.7. Leuk Res. 2014 Nov; 38(11):1320-6. PMID: 25241275.
      View in: PubMed
    5. Tuscano JM, Dutia M, Chee K, Brunson A, Reed-Pease C, Abedi M, Welborn J, O'Donnell RT. Lenalidomide plus rituximab can produce durable clinical responses in patients with relapsed or refractory, indolent non-Hodgkin lymphoma. Br J Haematol. 2014 May; 165(3):375-81. PMID: 24606326.
      View in: PubMed
    6. Kato J, O'Donnell RT, Abuhay M, Tuscano JM. Efficacy and toxicity of a CD22-targeted antibody-saporin conjugate in a xenograft model of non-Hodgkin's lymphoma. Oncoimmunology. 2012 Dec 01; 1(9):1469-1475. PMID: 23264893.
      View in: PubMed
    7. Kato J, Satake N, O'Donnell RT, Abuhay M, Lewis C, Tuscano JM. Efficacy of a CD22-targeted antibody-saporin conjugate in a xenograft model of precursor-B cell acute lymphoblastic leukemia. Leuk Res. 2013 Jan; 37(1):83-8. PMID: 23040543.
      View in: PubMed
    8. Tuscano JM, Kato J, Pearson D, Xiong C, Newell L, Ma Y, Gandara DR, O'Donnell RT. CD22 antigen is broadly expressed on lung cancer cells and is a target for antibody-based therapy. Cancer Res. 2012 Nov 01; 72(21):5556-65. PMID: 22986740.
      View in: PubMed
    9. Kato J, Li Y, Xiao K, Lee JS, Luo J, Tuscano JM, O'Donnell RT, Lam KS. Disulfide cross-linked micelles for the targeted delivery of vincristine to B-cell lymphoma. Mol Pharm. 2012 Jun 04; 9(6):1727-35. PMID: 22530955; PMCID: PMC4560237.
    10. Martin SM, Churchill E, McKnight H, Mahaffey CM, Ma Y, O'Donnell RT, Tuscano JM. The HB22.7 Anti-CD22 monoclonal antibody enhances bortezomib-mediated lymphomacidal activity in a sequence dependent manner. J Hematol Oncol. 2011 Dec 01; 4:49. PMID: 22128838; PMCID: PMC3287147.
    11. Tuscano JM, Ma Y, Martin SM, Kato J, O'Donnell RT. The Bs20x22 anti-CD20-CD22 bispecific antibody has more lymphomacidal activity than do the parent antibodies alone. Cancer Immunol Immunother. 2011 Jun; 60(6):771-80. PMID: 21347809; PMCID: PMC3098984.
    12. Tuscano JM, Martin SM, Ma Y, Zamboni W, O'Donnell RT. Efficacy, biodistribution, and pharmacokinetics of CD22-targeted pegylated liposomal doxorubicin in a B-cell non-Hodgkin's lymphoma xenograft mouse model. Clin Cancer Res. 2010 May 15; 16(10):2760-8. PMID: 20460479.
      View in: PubMed
    13. O'Donnell RT, Ma Y, McKnight HC, Pearson D, Tuscano JM. Dose, timing, schedule, and the choice of targeted epitope alter the efficacy of anti-CD22 immunotherapy in mice bearing human lymphoma xenografts. Cancer Immunol Immunother. 2009 Dec; 58(12):2051-8. PMID: 19437017; PMCID: PMC2749165.
    14. O'Donnell RT, Martin SM, Ma Y, Zamboni WC, Tuscano JM. Development and characterization of CD22-targeted pegylated-liposomal doxorubicin (IL-PLD). Invest New Drugs. 2010 Jun; 28(3):260-7. PMID: 19306119; PMCID: PMC2850518.
    15. O'Donnell RT, Pearson D, McKnight HC, Ma YP, Tuscano JM. Treatment of non-Hodgkin's lymphoma xenografts with the HB22.7 anti-CD22 monoclonal antibody and phosphatase inhibitors improves efficacy. Cancer Immunol Immunother. 2009 Oct; 58(10):1715-22. PMID: 19294384.
      View in: PubMed
    16. O'Donnell RT, Pearson D, McKnight HC, Ma YP, Tuscano JM. Phosphatase inhibition augments anti-CD22-mediated signaling and cytotoxicity in non-hodgkin's lymphoma cells. Leuk Res. 2009 Jul; 33(7):964-9. PMID: 19237192.
      View in: PubMed
    17. Martin SM, O'Donnell RT, Kukis DL, Abbey CK, McKnight H, Sutcliffe JL, Tuscano JM. Imaging and pharmacokinetics of (64)Cu-DOTA-HB22.7 administered by intravenous, intraperitoneal, or subcutaneous injection to mice bearing non-Hodgkin's lymphoma xenografts. Mol Imaging Biol. 2009 Mar-Apr; 11(2):79-87. PMID: 18949521.
      View in: PubMed
    18. Schillaci O, DeNardo GL, DeNardo SJ, Goldstein DS, Kroger LA, O'Donnell RT, Lamborn KR. Effect of antilymphoma antibody, 131I-Lym-1, on peripheral blood lymphocytes in patients with non-Hodgkin's lymphoma. Cancer Biother Radiopharm. 2007 Aug; 22(4):521-30. PMID: 17803447.
      View in: PubMed
    19. Semrad TJ, O'Donnell R, Wun T, Chew H, Harvey D, Zhou H, White RH. Epidemiology of venous thromboembolism in 9489 patients with malignant glioma. J Neurosurg. 2007 Apr; 106(4):601-8. PMID: 17432710.
      View in: PubMed
    20. Lehmann J, DeNardo GL, Yuan A, Shen S, O'Donnell RT, Richman CM, DeNardo SJ. Comparison of normal tissue pharmacokinetics with 111In/90Y monoclonal antibody m170 for breast and prostate cancer. Int J Radiat Oncol Biol Phys. 2006 Nov 15; 66(4):1192-8. PMID: 16965873.
      View in: PubMed
    21. O'Donnell RT. Nuclear localizing sequences: an innovative way to improve targeted radiotherapy. J Nucl Med. 2006 May; 47(5):738-9. PMID: 16644741.
      View in: PubMed
    22. Shen S, DeNardo GL, Yuan A, Hartmann-Siantar C, O'Donnell RT, DeNardo SJ. Splenic volume change and nodal tumor response in non-Hodgkin's lymphoma patients after radioimmunotherapy using radiolabeled Lym-1 antibody. Cancer Biother Radiopharm. 2005 Dec; 20(6):662-70. PMID: 16398618.
      View in: PubMed
    23. Richman CM, Denardo SJ, O'Donnell RT, Yuan A, Shen S, Goldstein DS, Tuscano JM, Wun T, Chew HK, Lara PN, Kukis DL, Natarajan A, Meares CF, Lamborn KR, DeNardo GL. High-dose radioimmunotherapy combined with fixed, low-dose paclitaxel in metastatic prostate and breast cancer by using a MUC-1 monoclonal antibody, m170, linked to indium-111/yttrium-90 via a cathepsin cleavable linker with cyclosporine to prevent human anti-mouse antibody. Clin Cancer Res. 2005 Aug 15; 11(16):5920-7. PMID: 16115934.
      View in: PubMed
    24. Shen S, DeNardo SJ, Richman CM, Yuan A, Siantar CH, O'Donnell RT, Kroger LA, DeNardo GL. Planning time for peripheral blood stem cell infusion after high-dose targeted radionuclide therapy using dosimetry. J Nucl Med. 2005 Jun; 46(6):1034-41. PMID: 15937317.
      View in: PubMed
    25. Martel CL, Li Y, Beckett L, Chew H, Christensen S, Davies A, Lam KS, Lau DH, Meyers FJ, O'donnell RT, Richman C, Scudder S, Tanaka M, Tuscano J, Welborn J, Wun T, Gandara DR, Lara PN. An evaluation of barriers to accrual in the era of legislation requiring insurance coverage of cancer clinical trial costs in California. Cancer J. 2004 Sep-Oct; 10(5):294-300. PMID: 15530258.
      View in: PubMed
    26. DeNardo SJ, DeNardo GL, Yuan A, Richman CM, O'Donnell RT, Lara PN, Kukis DL, Natarajan A, Lamborn KR, Jacobs F, Siantar CL. Enhanced therapeutic index of radioimmunotherapy (RIT) in prostate cancer patients: comparison of radiation dosimetry for 1,4,7,10-tetraazacyclododecane-N,N',N",N"'-tetraacetic acid (DOTA)-peptide versus 2IT-DOTA monoclonal antibody linkage for RIT. Clin Cancer Res. 2003 Sep 01; 9(10 Pt 2):3938S-44S. PMID: 14506192.
      View in: PubMed
    27. DeNardo SJ, Yao Z, Lam KS, Song A, Burke PA, Mirick GR, Lamborn KR, O'Donnell RT, DeNardo GL. Effect of molecular size of pegylated peptide on the pharmacokinetics and tumor targeting in lymphoma-bearing mice. Clin Cancer Res. 2003 Sep 01; 9(10 Pt 2):3854S-64S. PMID: 14506183.
      View in: PubMed
    28. DeNardo G, Yuan A, Goldstein D, Richman C, O'Donnell R, Shen S, Hartmann Siantar C, DeNardo S. Impact of interpatient pharmacokinetic variability on design considerations for therapy with radiolabeled MAbs. Cancer Biother Radiopharm. 2003 Apr; 18(2):231-7. PMID: 12804049.
      View in: PubMed
    29. Tuscano JM, O'Donnell RT, Miers LA, Kroger LA, Kukis DL, Lamborn KR, Tedder TF, DeNardo GL. Anti-CD22 ligand-blocking antibody HB22.7 has independent lymphomacidal properties and augments the efficacy of 90Y-DOTA-peptide-Lym-1 in lymphoma xenografts. Blood. 2003 May 01; 101(9):3641-7. PMID: 12511412.
      View in: PubMed
    30. Hutchinson K, Kopko PM, Muto KN, Tuscano J, O'Donnell RT, Holland PV, Richman C, Paglieroni TG, Wun T. Early diagnosis and successful treatment of a patient with transfusion-associated GVHD with autologous peripheral blood progenitor cell transplantation. Transfusion. 2002 Dec; 42(12):1567-72. PMID: 12473136.
      View in: PubMed
    31. O'Donnell RT, DeNardo SJ, Miers LA, Lamborn KR, Kukis DL, DeNardo GL, Meyers FJ. Combined modality radioimmunotherapy for human prostate cancer xenografts with taxanes and 90yttrium-DOTA-peptide-ChL6. Prostate. 2002 Jan 01; 50(1):27-37. PMID: 11757033.
      View in: PubMed
    32. O'Donnell RT, Shen S, Denardo SJ, Wun T, Kukis DL, Goldstein DS, Denardo GL. A phase I study of 90Y-2IT-BAD-Lym-1 in patients with non-Hodgkin's lymphoma. Anticancer Res. 2000 Sep-Oct; 20(5C):3647-55. PMID: 11268433.
      View in: PubMed
    33. O'Donnell RT, DeNardo SJ, DeNardo GL, Miers L, Lamborn KR, Kukis DL, Meyers FJ. Efficacy and toxicity of radioimmunotherapy with (90)Y-DOTA-peptide-ChL6 for PC3-tumored mice. Prostate. 2000 Aug 01; 44(3):187-92. PMID: 10906734.
      View in: PubMed
    34. O'Donnell RT, DeNardo SJ, Miers LA, Kukis DL, Mirick GR, Kroger LA, DeNardo GL. Combined modality radioimmunotherapy with Taxol and 90Y-Lym-1 for Raji lymphoma xenografts. Cancer Biother Radiopharm. 1998 Oct; 13(5):351-61. PMID: 10851425.
      View in: PubMed
    35. O'Donnell RT, DeNardo SJ, Shi XB, Mirick GR, DeNardo GL, Kroger LA, Meyers FJ. L6 monoclonal antibody binds prostate cancer. Prostate. 1998 Oct 01; 37(2):91-7. PMID: 9759703.
      View in: PubMed